Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Change in Account Payables (2016 - 2025)

Iradimed (IRMD) has disclosed Change in Account Payables for 13 consecutive years, with $432494.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Account Payables rose 49.62% to $432494.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $49271.0, a 104.07% increase, with the full-year FY2024 number at -$861618.0, down 298.09% from a year prior.
  • Change in Account Payables was $432494.0 for Q3 2025 at Iradimed, up from -$689064.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $1.6 million in Q2 2023 to a low of -$1.2 million in Q3 2023.
  • A 5-year average of $27073.7 and a median of $47490.0 in 2021 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 2190.24% in 2022; the steepest drop was 6104.67% in 2022.
  • Iradimed's Change in Account Payables stood at $47490.0 in 2021, then skyrocketed by 2190.24% to $1.1 million in 2022, then crashed by 167.68% to -$736084.0 in 2023, then skyrocketed by 47.32% to -$387798.0 in 2024, then soared by 211.53% to $432494.0 in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Change in Account Payables are $432494.0 (Q3 2025), -$689064.0 (Q2 2025), and $693639.0 (Q1 2025).